Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Goodwill & Intangibles (2021 - 2025)

Historic Goodwill & Intangibles for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to $2.9 million.

  • InMed Pharmaceuticals' Goodwill & Intangibles changed 0.0% to $2.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.9 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $2.9 million for FY2025, which is 0.0% changed from last year.
  • Per InMed Pharmaceuticals' latest filing, its Goodwill & Intangibles stood at $2.9 million for Q4 2025, which was down 0.0% from $2.9 million recorded in Q3 2025.
  • InMed Pharmaceuticals' Goodwill & Intangibles' 5-year high stood at $4.7 million during Q4 2021, with a 5-year trough of $1.7 million in Q3 2021.
  • Over the past 5 years, InMed Pharmaceuticals' median Goodwill & Intangibles value was $2.9 million (recorded in 2023), while the average stood at $2.9 million.
  • The largest annual percentage gain for InMed Pharmaceuticals' Goodwill & Intangibles in the last 5 years was 8990.51% (2023), contrasted with its biggest fall of 5753.77% (2023).
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' Goodwill & Intangibles stood at $4.7 million in 2021, then tumbled by 56.68% to $2.0 million in 2022, then surged by 44.43% to $2.9 million in 2023, then changed by 0.0% to $2.9 million in 2024, then changed by 0.0% to $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q4 2025, $2.9 million for Q3 2025, and $2.9 million during Q2 2025.